Redhill Biopharma Ltd
RDHL1.070USD
+0.040+3.88%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
3.56MValor de mercado
0.02P/L TTM
Mais detalhes de Redhill Biopharma Ltd Empresa
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Informações de Redhill Biopharma Ltd
Código da empresaRDHL
Nome da EmpresaRedhill Biopharma Ltd
Data de listagemFeb 01, 2011
CEOBen-Asher (Dror)
Número de funcionários35
Tipo de títulosDepository Receipt
Fim do ano fiscalFeb 01
Endereço21 Ha'arba'a St.
CidadeTEL AVIV-YAFO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIsrael
Código postal6473921
Telefone97235413131
Sitehttps://www.redhillbio.com/
Código da empresaRDHL
Data de listagemFeb 01, 2011
CEOBen-Asher (Dror)
Executivos da empresa Redhill Biopharma Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Eric Swenden
Mr. Eric Swenden
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Gilead Raday
Mr. Gilead Raday
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Guy Goldberg, J.D.
Mr. Guy Goldberg, J.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Rick D. Scruggs
Mr. Rick D. Scruggs
Chief Commercial Officer, Director
Chief Commercial Officer, Director
--
--
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Eric Swenden
Mr. Eric Swenden
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Gilead Raday
Mr. Gilead Raday
Chief Operating Officer
Chief Operating Officer
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sáb, 3 de jan
Atualizado em: sáb, 3 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Gagnon Securities LLC
0.35%
GAMMA Investing LLC
0.09%
Desjardins Securities Inc.
0.07%
Rhumbline Advisers Ltd. Partnership
0.03%
Outro
99.46%
Investidores
Investidores
Proporção
Gagnon Securities LLC
0.35%
GAMMA Investing LLC
0.09%
Desjardins Securities Inc.
0.07%
Rhumbline Advisers Ltd. Partnership
0.03%
Outro
99.46%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
0.44%
Research Firm
0.07%
Investment Advisor
0.04%
Outro
99.45%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
36
28.22K
0.55%
-60.13K
2025Q3
38
103.50K
3.11%
-21.59K
2025Q2
39
100.72K
4.39%
-24.30K
2025Q1
45
100.27K
5.67%
-27.27K
2024Q4
61
86.70K
6.77%
-35.73K
2024Q3
77
75.64K
5.91%
-52.57K
2024Q2
82
147.72K
11.56%
-10.64K
2024Q1
84
175.94K
13.78%
+109.25K
2023Q4
94
19.30K
14.67%
-65.78K
2023Q3
106
74.17K
44.30%
+53.53K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Gagnon Securities LLC
17.82K
0.35%
+17.82K
--
Sep 30, 2025
GAMMA Investing LLC
4.83K
0.09%
+4.69K
+3476.30%
Dec 31, 2025
Desjardins Securities Inc.
3.39K
0.07%
--
--
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
1.77K
0.03%
--
--
Sep 30, 2025
BofA Global Research (US)
303.00
0.01%
--
--
Sep 30, 2025
EverSource Wealth Advisors, LLC
38.00
0%
+38.00
--
Sep 30, 2025
The Advocates
19.00
0%
+19.00
--
Sep 30, 2025
Rothschild Investment Corporation
17.00
0%
+17.00
--
Sep 30, 2025
UBS Switzerland AG
16.00
0%
+15.00
+1500.00%
Sep 30, 2025
Group One Trading, L.P.
11.00
0%
--
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Data
Data ex-dividendo
Tipo
Proporção
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
